Autophagy — the cellular recycling system — declines with age and is activated by rapamycin, fasting, and exercise. Here is what the evidence shows for interventions that target it.
Autophagy is the process by which cells recycle their own damaged components — organelles, misfolded proteins, aggregated macromolecules — through a lysosomal degradation pathway. Its decline with age is one of the central mechanisms linking cellular aging to disease.
The word comes from the Greek for self-eating — and autophagy discovery was awarded the 2016 Nobel Prize in Physiology or Medicine to Yoshinori Ohsumi. Autophagy is not simply cellular garbage collection; it is a precisely regulated quality-control system that removes not just random cellular debris but specifically targets damaged mitochondria (mitophagy), aggregated proteins (aggrephagy), and intracellular pathogens. Its decline with age allows these damaged components to accumulate, driving inflammation, mitochondrial dysfunction, and proteostatic collapse.
Rapamycin: the most potent pharmacological autophagy inducer available, through mTORC1 inhibition — the primary brake on autophagy initiation. ITP confirmed lifespan extension; PEARL trial showed immune benefits. Fasting and caloric restriction: the most studied physiological autophagy inducer. Cellular autophagy increases within hours of food deprivation. Clinical intermittent fasting protocols vary widely in their ability to achieve meaningful autophagic flux. Urolithin A: activates mitophagy specifically through the PINK1/Parkin pathway — the most targeted autophagy activator in the longevity supplement space, with two positive small RCTs. Exercise: acute exercise activates autophagy in multiple tissues; the magnitude and duration required to produce clinically meaningful autophagic flux in humans is not established. Spermidine: polyamine that induces autophagy through eIF5A hypusination; epidemiological data and one small RCT.
Disabled macroautophagy is one of the twelve hallmarks of aging identified by Lopez-Otin et al. The accumulation of damaged mitochondria drives reactive oxygen species production and inflammation. The accumulation of misfolded proteins contributes to neurodegeneration — Alzheimer's, Parkinson's, and many other neurodegenerative diseases involve autophagy failure in specific cell types. Restoration of autophagy function in aged mice — through rapamycin, caloric restriction, or genetic manipulation — consistently improves multiple aging phenotypes. The challenge for clinical translation is that autophagy is a complex, multi-pathway process, and the relationship between surrogate autophagy biomarkers and hard clinical outcomes in humans has not been established.
Autophagy is one of the most mechanistically important processes in aging biology, and several longevity interventions — rapamycin, Urolithin A, fasting, exercise — activate it through different mechanisms. The clinical challenge is that no approved intervention has been shown to extend human lifespan through autophagy activation, and the measurement of autophagy in clinical settings remains technically challenging. The strongest evidence for autophagy-mediated longevity benefit in humans remains inferential — consistent with the pathway's importance but not directly demonstrated through hard outcome trials.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.